RA
PVLA

Royce & Associates’s Palvella Therapeutics PVLA Stock Holding History

Royce & Associates’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.93M Buy
31,507
+1,497
+5% +$156K 0.04% 497
2025
Q4 		$3.14M Sell
30,010
-19,499
-39% -$1.66M 0.03% 538
2025
Q3 		$3.1M Sell
49,509
-25,007
-34% -$1.12M 0.03% 539
2025
Q2 		$1.68M Buy
74,516
+3,002
+4% +$70.5K 0.02% 619
2025
Q1 		$2M Buy
+71,514
New +$1.38M 0.02% 586
2018
Q4 		– Sell
-39
Closed -$18K – 1207
2018
Q3 		$18K Buy
39
+17
+77% +$7.39K ﹤0.01% 1159
2018
Q2 		$9K Buy
22
+15
+214% +$7.14K ﹤0.01% 1206
2018
Q1 		$4K Sell
7
-2
-22% -$1.24K ﹤0.01% 1247
2017
Q4 		$6K Buy
+9
New +$4.18K ﹤0.01% 1232

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return